Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

AstraZeneca Files Suit against FDA over Generic Seroquel

By Pharmaceutical Processing | March 13, 2012

AstraZeneca announced Tuesday that the company filed a lawsuit against the FDA seeking to overturn the agency’s recent decision rejecting two Citizen Petitions for Seroquel (quetiapine). The drugmaker said it “will vigorously defend its legal rights.”

The company wants an injunction barring the regulator from granting final marketing approval of generic versions of the immediate-release form of Seroquel until December 2, when regulatory exclusivity expires on certain clinical trial data, or until a federal court has “a meaningful opportunity to review imminent FDA action regarding the pending generic marketing applications.” AstraZeneca filed the two petitions last year asking that generic versions of Seroquel contain similar warnings to the branded versions about blood sugar levels and possible suicide.

Generic versions of the immediate-release product are due to be launched in the U.S. on March 26 when AstraZeneca’s patent expires. Panmure analyst Savvas Neophytou said that the drugmaker’s chance of overturning the FDA ruling is a “low probability event,” adding that “if the company is successful in keeping generics out until 2 December, it would result in around 15 percent EPS upgrades to consensus. Some will view this as a windfall.”

Seroquel generated annual revenue of $5.8 billion last year.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE